BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China to downgrade COVID-19 management to Class B

In a statement released late Monday, the National Health Commission (NHC) renamed the Chinese term for COVID-19 from "novel coronavirus pneumonia" to "nove...

December 28, 2022 | News

Ablaze Pharmaceuticals and Yonghe Pharma Initiate Development and Manufacturing Services Agreement for Targeted Radiopharmaceutical Therapies

"This agreement with Yonghe represents a significant step for Ablaze in our efforts to optimize our preclinical and clinical development program for target...

December 28, 2022 | News

Brii Biosciences Provides Update on Strategic Clinical Development Progress

Initiation of Phase 2 postpartum depression (PPD) study planned for early 2023 to advance potential first-of-its-kind treatment U.S. FDA lifted clinical h...

December 28, 2022 | News

China Covid19 Surge : Coronavirus Pandemic Country Profile

What is important to note about these case figures? The reported case figures on a given date do not necessarily show the number of new cases on that da...

December 22, 2022 | News

Cell and Gene Therapy Companies Leverage GenScript's cGMP sgRNA Capability to Accelerate Speed to Market

GenScript USA Inc., the world's leading life-science service provider, recently expanded its global current Good Manufacturing Practices (cGMP)&n...

December 19, 2022 | News

Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone

Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highlights Everest's discovery capabilities Clinically valida...

December 15, 2022 | News

Ascletis Announces Positive Phase I Clinical Results of Oral RdRp Inhibitor ASC10 for COVID-19

Based on Ascletis' Phase I results of ASC10 and molnupiravir's clinical efficacy data in American, Japanese and Chinese patients, 800 mg twice daily of ASC...

December 13, 2022 | News

China further optimizes COVID-19 response with new measures

Local authorities across China have soon made specific policies to implement the 10 new prevention and control measures recently rolled out by th...

December 12, 2022 | News

Thermo Fisher Scientific Expands its Global Biologics and Steriles Manufacturing Capabilities in China

Thermo Fisher Scientific, the world leader in serving science, is opening a new facility in Hangzhou, China, as part of its global effort to help comp...

December 08, 2022 | News

Antengene Appoints Amily Zhang as its Chief Medical Officer

Before joining Antengene, Ms. Zhang served in various key leadership positions in clinical development at Jiangsu Hengrui Pharmaceuticals (or "Hengrui...

December 08, 2022 | News

HUMAN celebrates its 50th anniversary

From reagent specialist to global player with a broad network of long-standing distribution partners in more than 160 countries • Covering a compre...

December 05, 2022 | News

WuXi STA Launches Another Parenteral Formulation Manufacturing Line at Wuxi city site

This new line features a fully automatic vial loading/unloading system and a built-in 15 m2 lyophilizer in a fully enclosed isolator. The filling line...

December 01, 2022 | News

WuXi AppTec Begins Construction of Wuxi STA Pharmaceutical East China R&D Facility

WuXi AppTec recently held the groundbreaking ceremony for its Wuxi STA Pharmaceutical East China R&D facility in tandem with the signing ceremony...

November 24, 2022 | News

The 13th China (Taizhou) International Medical Expo successfully held

During the event, 20 projects with a total investment of about 7.1 billion yuan were signed intensively, covering fields such as vaccines, antibo...

November 24, 2022 | News

Stay Connected